staceywhite, Author at European Medical Journal - Page 48 of 195

EMJ

Improving Bronchiectasis Management

Five Considerations when Selecting Adjunctive Treatment for Drug-Resistant Epilepsy

This infographic explores five key considerations when adjunctive treatments for drug-resistant epilepsy (DRE) are added to an existing…

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Masterclass Event Summary

A masterclass initiated, organised, and funded by UCB, sought to advance understanding and expertise of myelin oligodendrocyte…

Understanding Micro-CT Scanning

This infographic details the workings and applications of micro-CT scanning, exploring the advantages of this imaging method in every day…

Updates in BRAF V600E-Mutated mCRC

The BRAF V600E mutation occurs in 8–12% of patients with metastatic colorectal cancer, and is associated with poor prognosis. This…

Impact of Non-Seizure Symptoms in Dravet Syndrome and Lennox-Gastaut Syndrome

Non-seizure symptoms in Dravet and Lennox-Gastaut syndromes can affect speech, gait, appetite, mood, development, and sleep and impact…

Latest Spring Journal Out Now!

Explore this new issue showcasing multidisciplinary healthcare and other pertinent topics, including contraceptive use among females with…

Non-Factor Therapies in Current Clinical Practice

The 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) took place on 6th–9th February 2024 in…

Sparsentan for treatment of immunoglobulin A nephropathy: Latest study results

In patients with immunoglobulin A nephropathy, use of the endothelin 1 Type A/Ang II subtype 1 receptor antagonist sparsentan can decrease proteinuria and preserve kidney function

Transitioning Patients From Second- to First-Line Prophylaxis in Hereditary Angioedema

Targetted prophylaxis is recommended for people with HAE, but many remain on attenuated androgens. EMJ spoke to two HAE experts who explain how they help patients to make the switch.